文献速递结核与非结核分枝杆菌艾滋病与性传播感染

血浆生物标志物检测HIV-1感染者中现患或预测进展性结核病

Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus-1.
PubMed 文献 · Clin Infect Dis · 2019-01-01

未刺激样本中CXCL10、IL-2等浓度在结核组更高,模型区分对照组与现患结核的AUC达0.9,但区分对照组与incident结核能力差。结论认为单一标志物不足以区分疾病状态,需联合标志物,且检测现患结核可能具有重要价值。

要点

  • 未刺激血浆中CXCL10、IL-2、IL-1α、TGF-α在现患和incident结核组浓度高于对照组。
  • 基于未刺激分析物的模型区分对照组与现患结核的AUC=0.9,区分incident与现患结核的AUC>0.8。
  • 模型区分对照组与incident结核能力差,且背景校正后模型表现不佳。

核心结论

  • 单一血浆生物标志物难以区分HIV-1共感染者的结核病状态,需联合标志物。
  • 检测现患结核的能力可能重要,因尚无血液检测被提示可用于HIV-1共感染者中检测现患结核。

研究设计与样本

  • 在随机对照异烟肼预防治疗试验的筛查和入组阶段招募421名HIV-1感染者。
  • 将个体分为现患结核组、incident结核组和对照组,应用组间比较、监督学习和加权相关网络分析。

主要发现

  • 未刺激样本中,现患和incident结核组的分析物浓度高于对照组。
  • 最大差异见于CXCL10、IL-2、IL-1α、TGF-α。
  • 使用未刺激分析物的预测模型区分对照组与现患结核最佳(AUC=0.9),区分incident与现患结核尚可(AUC>0.8),区分对照组与incident结核较差。
  • 未刺激IL-2和IFN-γ在除对照组与incident结核比较外的所有比较中排名靠前。
  • 使用背景校正值的模型表现不佳。

临床怎么用

  • 血浆生物标志物组合可能有助于检测HIV-1感染者中的现患结核,但尚不能可靠预测进展。
  • 临床不应依赖单一标志物区分HIV-1感染者的结核病状态。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The risk of individuals infected with human immunodeficiency virus (HIV)-1 developing tuberculosis (TB) is high, while both prognostic and diagnostic tools remain insensitive. The potential for plasma biomarkers to predict which HIV-1-infected individuals are likely to progress to active disease is unknown. METHODS: Thirteen analytes were measured from QuantiFERON Gold in-tube (QFT) plasma samples in 421 HIV-1-infected persons recruited within the screening and enrollment phases of a randomized, controlled trial of isoniazid preventive therapy. Blood for QFT was obtained pre-randomization. Individuals were classified into prevalent TB, incident TB, and control groups. Comparisons between groups, supervised learning methods, and weighted correlation network analyses were applied utilizing the unstimulated and background-corrected plasma analyte concentrations. RESULTS: Unstimulated samples showed higher analyte concentrations in the prevalent and incident TB groups compared to the control group. The largest differences were seen for C-X-C motif chemokine 10 (CXCL10), interleukin-2 (IL-2), IL-1α, transforming growth factor-α (TGF-α). A predictive model analysis using unstimulated analytes discriminated best between the control and prevalent TB groups (area under the curve [AUC] = 0.9), reasonably well between the incident and prevalent TB groups (AUC > 0.8), and poorly between the control and incident TB groups. Unstimulated IL-2 and IFN-γ were ranked at or near the top for all comparisons, except the comparison between the control vs incident TB groups. Models using background-adjusted values performed poorly. CONCLUSIONS: Single plasma biomarkers are unlikely to distinguish between disease states in HIV-1 co-infected individuals, and combinations of biomarkers are required. The ability to detect prevalent TB is potentially important, as no blood test hitherto has been suggested as having the utility to detect prevalent TB amongst HIV-1 co-infected persons.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Lesosky M, Rangaka MX, Pienaar C, et al. Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus-1. Clin Infect Dis. 2019. PMID: 30256919. doi:10.1093/cid/ciy823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。